Literature DB >> 22749856

Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications.

Xiangyu Kong1, Lei Li, Zhaoshen Li, Keping Xie.   

Abstract

Pancreatic cancer is one of the most lethal malignancies, with a prominent desmoplastic reaction as its defining hallmark. The past several decades have seen dramatic progress in understanding of pancreatic cancer pathogenesis, including identification of precursor lesions, sequential transformation from normal pancreatic tissue to invasive pancreatic cancer and corresponding signature genetic events, and the biological impact of these events on malignant behavior. However, the currently used therapeutic strategies for epithelial tumor cells, which have exhibited potent antitumor activity in cell culture and animal models, have failed to produce significant effects in the clinic. The desmoplastic stroma surrounding pancreatic cancer cells, which accounts for about 90% of a tumor's mass, clearly is not a passive scaffold for cancer cells but an active contributor to carcinogenesis. Improved understanding of the dynamic interaction between cancer cells and the stroma will be important to designing effective therapeutic strategies for pancreatic cancer. This review focuses on the origin of stromal molecular and cellular components in pancreatic tumors, their biological effects on pancreatic cancer cells, and the orchestration of these two components.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22749856      PMCID: PMC3505269          DOI: 10.1016/j.cytogfr.2012.06.006

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  150 in total

Review 1.  Myofibroblasts. I. Paracrine cells important in health and disease.

Authors:  D W Powell; R C Mifflin; J D Valentich; S E Crowe; J I Saada; A B West
Journal:  Am J Physiol       Date:  1999-07

Review 2.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

3.  Pain as a predictor of outcome in patients with operable pancreatic carcinoma.

Authors:  D P Kelsen; R Portenoy; H Thaler; Y Tao; M Brennan
Journal:  Surgery       Date:  1997-07       Impact factor: 3.982

4.  Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.

Authors:  Anne Juuti; Stig Nordling; Johan Lundin; Johanna Louhimo; Caj Haglund
Journal:  Oncology       Date:  2005-05-09       Impact factor: 2.935

5.  Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas.

Authors:  Ken-Ichi Okada; Kenichi Hirabayashi; Toshihide Imaizumi; Masahiro Matsuyama; Naoki Yazawa; Shoichi Dowaki; Kosuke Tobita; Yasuo Ohtani; Makiko Tanaka; Sadaki Inokuchi; Hiroyasu Makuuchi
Journal:  Biomed Res       Date:  2010-02       Impact factor: 1.203

6.  Sonic hedgehog promotes desmoplasia in pancreatic cancer.

Authors:  Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness.

Authors:  A Ginestra; M D La Placa; F Saladino; D Cassarà; H Nagase; M L Vittorelli
Journal:  Anticancer Res       Date:  1998 Sep-Oct       Impact factor: 2.480

9.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

Review 10.  Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers.

Authors:  Keping Xie; James L Abbruzzese
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

View more
  10 in total

1.  Generation of an in vitro 3D PDAC stroma rich spheroid model.

Authors:  Matthew J Ware; Vazrik Keshishian; Justin J Law; Jason C Ho; Carlos A Favela; Paul Rees; Billie Smith; Sayeeduddin Mohammad; Rosa F Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean P Edwards; Stuart J Corr; Biana Godin; Steven A Curley
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

Review 2.  Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer.

Authors:  Junli Guo; Keping Xie; Shaojiang Zheng
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

3.  Pancreatic cancer stromal biology and therapy.

Authors:  Dacheng Xie; Keping Xie
Journal:  Genes Dis       Date:  2015-06-01

4.  ADAM8 as a drug target in pancreatic cancer.

Authors:  Uwe Schlomann; Garrit Koller; Catharina Conrad; Taheera Ferdous; Panagiota Golfi; Adolfo Molejon Garcia; Sabrina Höfling; Maddy Parsons; Patricia Costa; Robin Soper; Maud Bossard; Thorsten Hagemann; Rozita Roshani; Norbert Sewald; Randal R Ketchem; Marcia L Moss; Fred H Rasmussen; Miles A Miller; Douglas A Lauffenburger; David A Tuveson; Christopher Nimsky; Jörg W Bartsch
Journal:  Nat Commun       Date:  2015-01-28       Impact factor: 14.919

Review 5.  Pancreatic Cancer Chemoresistance to Gemcitabine.

Authors:  Manoj Amrutkar; Ivar P Gladhaug
Journal:  Cancers (Basel)       Date:  2017-11-16       Impact factor: 6.639

6.  Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study.

Authors:  Fabio Grizzi; Sirio Fiorino; Dorina Qehajaj; Adele Fornelli; Carlo Russo; Dario de Biase; Michele Masetti; Laura Mastrangelo; Matteo Zanello; Raffaele Lombardi; Andrea Domanico; Esterita Accogli; Andrea Tura; Leonardo Mirandola; Maurizio Chiriva-Internati; Robert S Bresalier; Elio Jovine; Paolo Leandri; Luca Di Tommaso
Journal:  J Transl Med       Date:  2019-02-28       Impact factor: 5.531

7.  Risk Factors for Pancreatic Cancer in China: A Multicenter Case-Control Study.

Authors:  Zhaoxu Zheng; Rongshou Zheng; Yutong He; Xibin Sun; Ning Wang; Tianhui Chen; Wanqing Chen
Journal:  J Epidemiol       Date:  2015-10-03       Impact factor: 3.211

8.  Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia.

Authors:  Sujit Suklabaidya; Biswajit Das; Syed Azmal Ali; Sumeet Jain; Sharada Swaminathan; Ashok K Mohanty; Susen K Panda; Pujarini Dash; Subhankar Chakraborty; Surinder K Batra; Shantibhusan Senapati
Journal:  Oncotarget       Date:  2016-07-05

Review 9.  EMT and Treatment Resistance in Pancreatic Cancer.

Authors:  Nicola Gaianigo; Davide Melisi; Carmine Carbone
Journal:  Cancers (Basel)       Date:  2017-09-12       Impact factor: 6.639

10.  Possibility for Transcriptional Targeting of Cancer-Associated Fibroblasts-Limitations and Opportunities.

Authors:  Dina V Antonova; Marina V Zinovyeva; Liya G Kondratyeva; Alexander V Sass; Irina V Alekseenko; Victor V Pleshkan
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.